表纸
市场调查报告书

全球非酒精性脂肪性肝炎(NASH)治疗药物市场:COVID-19潜在影响的见解和预测(2020-2029)

Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)

出版商 Koncept Analytics 商品编码 948344
出版日期 内容资讯 英文 102 Pages
订单完成后即时交付
价格
全球非酒精性脂肪性肝炎(NASH)治疗药物市场:COVID-19潜在影响的见解和预测(2020-2029) Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029)
出版日期: 2020年07月09日内容资讯: 英文 102 Pages
简介

2029年,全球非酒精性脂肪性肝炎(NASH)治疗市场规模达到843.4亿美元。在2018年至2029年的预测期内,市场预计将以39.13%的复合年增长率增长。诸如医疗保健支出增加,药物研发支出增加,糖尿病人口急剧增加,肥胖人口增长,潜在需求以及久坐的生活方式等因素预计将推动市场增长。但是,顽固的药物批准程序,高昂的治疗成本以及NASH/NAFLD诊断的确定性低是市场上的挑战。市场上的显著趋势包括主要NASH药物的快速市场渗透,NASH流行率的提高,NASH诊断和生物标志物的发展,NASH管道药物的开发以及电子商务药物的销售增加。

本报告按市场增长因素,挑战,趋势和发展,COVID-19的影响,药物类型和地区来调查非酒精性脂肪性肝炎(NASH)治疗的全球市场。我们提供诸如市场分析,竞争状况和主要公司简介之类的信息。

内容

第1章市场概述

  • 简介
  • 原因和症状
  • 诊断
  • 处理
  • 标签外处理
  • 治疗性治疗

第2章COVID-19的影响

  • COVID-19病例数增加
  • 政府增加医疗费用
  • 增加生物标志物的应用
  • NASH治疗剂对临床试验的影响

第3章世界市场

  • 按销售量预测的市场
  • 销售(预测):按药品类别
  • 按销售分类的药品

第4章全球治疗□□药物市场

  • 销售预测
  • 按药物类型划分的市场销售预测
    • 2024年的预测
    • 2029年的预测
    • 奥贝胆酸(OCA)按销售额
    • 奥贝胆酸(OCA)按地区
    • Cenicriviroc(CVC)按销售额
    • Cenicriviroc(CVC)按地区
    • Elafibranor按销售额
    • Aramchol:按销售额
    • MGL-3196:按销售额
    • INN-217:按销售额
    • VK2809:按销售额
  • 按地区划分的市场销售预测
    • 2024年的预测
    • 2029年的预测

按地区划分的第五章市场预测

  • 美国
  • 欧洲
  • 其他地区

第6章市场动态

  • 生长因子
    • 医疗保健支出增加
    • 药品研发费用增加
    • 糖尿病人口正在迅速增加
    • 肥胖人口增加
    • 未满足的医疗需求
    • 不动身体的生活
  • 主要趋势与发展
    • 主要NASH药物迅速进入市场
    • NASH患病率上升
    • 持续的NASH诊断方法和生物标志物
    • NASH管道药物正在开发中
    • 电子商务药品销售增长
  • 挑战
    • 药品审批流程
    • 治疗费用高
    • 相关业务风险
    • NASH/NAFLD的非确定性诊断方法

第7章竞争情况

  • 世界市场
    • 主要公司:收入比较
    • 主要公司:市值比较
    • 主要公司:研发比较
    • 公司:产品组合比较

第8章公司简介

  • Bristol Myers Squibb
  • Gilead Sciences, Inc.
  • Allergan (Abbvie)
  • Intercept Pharmaceuticals, Inc.
  • Galmed Pharmaceuticals
  • Genfit SA
目录

The global non-alcoholic steatohepatitis (NASH) drugs market is expected to reach US$84.34 billion in 2029, growing at a CAGR of 39.13%, for the duration spanning 2018-2029. The factors such as rising healthcare expenditure, increasing pharmaceutical R&D expenditure, surging diabetic population, escalating obese population, unmet medical needs and sedentary lifestyles are expected to drive the growth of the market. However, the market growth would be challenged by lethargic drug approval process, high treatment cost and less definitive diagnostic methods for NASH/NAFLD. A few notable trends include surging market penetration for NASH major drugs, increasing prevalence of NASH, progressing NASH diagnosis methods and biomarkers, NASH pipeline drugs under development and growth in e-commerce pharmaceutical products sales.

The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market in coming years, with considerable market share. The need for definitive NASH treatment would lead to strong market penetration of the therapeutic drugs during the forecasted period.

The fastest growing regional market would be the U.S., due to the increasing prevalence of NASH, along with forthcoming launches of various NASH therapeutic drugs. Moreover, Europe is also expected to hold a significant share in the global NASH therapeutics market, owing to the growing awareness amongst the inhabitants, regarding NASH diagnosis and treatment methods.

Scope of the report:

The report provides a comprehensive analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market, segmented into Off Label Drugs and Therapeutic Drugs sub markets.

The major regional markets (the U.S., Europe and Rest of World) have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Bristol Myers Squibb, Gilead Sciences, Allergan Plc. (Tobira), Intercept Pharmaceuticals, Galmed Pharmaceuticals and Genfit SA) are also presented in detail.

Key Target Audience:

  • NAFLD/NASH Drugs Manufacturers
  • Chemical Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Causes & Symptoms
  • 1.3. Diagnosis
  • 1.4. Treatment
  • 1.5. Off-Label Treatment
  • 1.6. Therapeutic Treatment

2. Impact of COVID-19

  • 2.1. Rise in Number of COVID-19 Cases
  • 2.2. Growth in Government Spending on Healthcare
  • 2.3. Rise in Application of Biomarkers
  • 2.4. Impact on NASH Therapeutics Clinical Trials

3. Global NASH Market

  • 3.1. Global NASH Drugs Market Forecast by Value
  • 3.2. Global NASH Drugs Market Value Forecast by Drug Class
  • 3.3. Global NASH Off-Label Drugs Market Forecast by Value

4. Global NASH Therapeutics Market

  • 4.1. Global NASH Therapeutics Market Forecast by Value
  • 4.2. Global NASH Therapeutics Market Value Forecast by Drug Type
    • 4.2.1. Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
    • 4.2.2. Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
    • 4.2.3. Global Obeticholic Acid (OCA) Drug Market Forecast by Value
    • 4.2.4. Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region
    • 4.2.5. Global Cenicriviroc (CVC) Drug Market Forecast by Value
    • 4.2.6. Global Cenicriviroc (CVC) Drug Market Value Forecast by Region
    • 4.2.7. Global Elafibranor Drug Market Forecast by Value
    • 4.2.8. Global Aramchol Drug Market Forecast by Value
    • 4.2.9. Global MGL-3196 Drug Market Forecast by Value
    • 4.2.10. Global INN-217 Drug Market Forecast by Value
    • 4.2.11. Global VK2809 Drug Market Forecast by Value
  • 4.3. Global NASH Therapeutics Market Value Forecast by Region
    • 4.3.1. Global NASH Therapeutics Market Value Forecast by Region (2024)
    • 4.3.2. Global NASH Therapeutics Market Value Forecast by Region (2029)

5. Regional NASH Market

  • 5.1. The U.S. NASH Therapeutics Market Forecast by Value
  • 5.2. Europe NASH Therapeutics Market Forecast by Value
  • 5.3. ROW NASH Therapeutics Market Forecast by Value

6. Market Dynamics

  • 6.1. Growth Drivers
    • 6.1.1. Rising HealthCare Expenditure
    • 6.1.2. Increase in Pharmaceutical R&D Expenditures
    • 6.1.3. Surging Diabetic Population
    • 6.1.4. Escalating Obese Population
    • 6.1.5. Unmet Medical Needs
    • 6.1.6. Sedentary Lifestyle
  • 6.2. Key Trends & Development
    • 6.2.1. Surging Market Penetration for Major NASH Drugs
    • 6.2.2. Increasing Prevalence of NASH
    • 6.2.3. Progressing NASH Diagnosis Methods and Biomarkers
    • 6.2.4. NASH Pipeline Drugs Under Development
    • 6.2.5. Growth in E-Commerce Pharmaceutical Products Sales
  • 6.3. Challenges
    • 6.3.1. Lethargic Drug Approval Process
    • 6.3.2. High Treatment Cost
    • 6.3.3. Associated Business Risk
    • 6.3.4. Less Definitive Diagnostic Methods for NASH/NAFLD

7. Competitive Landscape

  • 7.1. Global NASH Drugs Market
    • 7.1.1. Key Players - Revenue Comparison
    • 7.1.2. Key Players - Market Cap Comparison
    • 7.1.3. Key Players - R&D Comparison
    • 7.1.4. Key Players - Product Portfolio Comparison

8. Company Profiles

  • 8.1. Bristol Myers Squibb
    • 8.1.1. Business Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Business Strategies
  • 8.2. Gilead Sciences, Inc.
    • 8.2.1. Business Overview
    • 8.2.2. Financial Overview
    • 8.2.3. Business Strategies
  • 8.3. Allergan (Abbvie)
    • 8.3.1. Business Overview
    • 8.3.2. Financial Overview
    • 8.3.3. Business Strategies
  • 8.4. Intercept Pharmaceuticals, Inc.
    • 8.4.1. Business Overview
    • 8.4.2. Financial Overview
    • 8.4.3. Business Strategies
  • 8.5. Galmed Pharmaceuticals
    • 8.5.1. Business Overview
    • 8.5.2. Financial Overview
    • 8.5.3. Business Strategies
  • 8.6. Genfit SA
    • 8.6.1. Business Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Business Strategies

List of Figures

  • NAFLD Spectrum and Estimated Advancement Risk
  • Treatment of NASH
  • Potential Phase III NASH Drugs
  • Global Government Share on Health Spending (2019-2024)
  • Global Biomarkers Market Value Forecast (2016-2021)
  • Global NASH Drugs Market Forecast by Value (2018-2029)
  • Global NASH Drugs Market Value Forecast by Drug Class (2019/2024/2029)
  • Global NASH Off-Label Drugs Market Forecast by Value (2018-2029)
  • Global NASH Therapeutics Market Forecast by Value (2020-2029)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2024)
  • Global NASH Therapeutics Market Value Forecast by Drug Type (2029)
  • Global Obeticholic Acid (OCA) Drug Market Forecast by Value (2020-2029)
  • Global Obeticholic Acid (OCA) Drug Market Value Forecast by Region (2029)
  • Global Cenicriviroc (CVC) Drug Market Forecast by Value (2020-2029)
  • Global Cenicriviroc (CVC) Drug Market Value Forecast by Region (2029)
  • Global Elafibranor Drug Market Forecast by Value (2020-2029)
  • Global Aramchol Drug Market Forecast by Value (2022-2029)
  • Global MGL-3196 Drug Market Forecast by Value (2023-2029)
  • Global INN-217 Drug Market Forecast by Value (2023-2029)
  • Global VK2809 Drug Market Forecast by Value (2023-2029)
  • Global NASH Therapeutics Market Value Forecast by Region (2024)
  • Global NASH Therapeutics Market Value Forecast by Region (2029)
  • The U.S. NASH Therapeutics Market Forecast by Value (2022-2029)
  • Europe NASH Therapeutics Market Forecast by Value (2022-2029)
  • ROW NASH Therapeutics Market Forecast by Value (2022-2029)
  • Global HealthCare Expenditure Per Capita (2014-2019)
  • Global Pharmaceutical R&D Expenditures (2014-2019)
  • Global Prevalence of Diabetes (2014-2019)
  • Global Obese Patient Population (2014-2019)
  • Number of NASH Patients treated with Ocaliva and Selonsertib Forecast (2020-2025)
  • The US NASH Patient Population (2018-2028)
  • Global E-Commerce Pharmaceutical Products Sales (2018-2023)
  • Drugs Approval Process
  • Bristol Myers Squibb Total Revenue and Net Earnings (2015-2019)
  • Bristol Myers Squibb Revenue by Segment (2019)
  • Bristol Myers Squibb Revenue by Region (2019)
  • Gilead Sciences Revenue and Net Income (2015-2019)
  • Gilead Sciences Revenue by Segment (2019)
  • Gilead Sciences Revenue by Region (2019)
  • Allergan Plc. (Abbvie) Net Revenue and Net Loss (2015-2019)
  • Allergan Plc. (Abbvie) Net Revenue by Segment (2019)
  • Intercept Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Intercept Pharmaceuticals Revenue by Segment (2019)
  • Galmed Pharmaceuticals Revenue and Net Loss (2015-2019)
  • Genfit SA Revenue and Net Loss (2015-2019)

List of Tables

  • NASH Off-Label Therapies
  • Total Confirmed COVID-19 Cases Worldwide (2020)
  • Selected NASH Diagnosis Methods and Biomarkers under Development (2019)
  • Drugs under Development for NASH (2019)
  • NASH Annual Treatment Cost Comparison (2019)
  • Key Players - Revenue Comparison (2019)
  • Key Players - Market Cap Comparison (2020)
  • Key Players - R&D Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Key Players - Product Portfolio Comparison (2019)
  • Intercept Pharmaceuticals Product Pipeline (2019)
  • Genfit SA Product Pipeline (2019)